Genefluidics

Overview

GeneFluidics was incorporated in 2000 to develop a fast, accurate, and simple testing system for improving worldwide health. By integrating novel bionano and microfluidic technologies, the company’s revolutionary platform enables complex tests that are normally performed only by skilled technicians in a laboratory to be performed by anyone, anywhere.

Originally conceived as part of a biodefense program, the platform integrates nanotechnology-enabled analyte detection with microfluidic-based automated sample preparation for rapid and accurate ‘plug and play’ use. For system operation, the user simply introduces a raw sample such as whole blood, urine, saliva, or water to a disposable cartridge, inserts this cartridge into a reader instrument, pushes a button, and waits 10-20 minutes for test results.

Mission Statement

GeneFluidics is committed to improving the quality of human life with advanced engineering technologies.

Management

Dr. Vincent Gau – Co-founder, CEO, President and CTO

Dr. Gau is a recognized international expert on bioMEMS, nanotechnology and microfluidics. He gained extensive high-volume, low-cost manufacturing, and product development experience while he worked for DYNA Image and United Microelectronics Corporation, the second largest integrated circuit foundry in the world. At UMC, Dr. Gau was a Project Leader in charge of managing numerous yield improvement projects and won the 1995 UMC Outstanding Engineer Award. Dr. Gau earned a B.S. in Electrical Engineering from Tamkang University in Taiwan, an M.S. in Electrical Engineering from UCLA, and was the recipient of the first Ph.D. awarded by UCLA in Biomedical Engineering. His Ph.D. simultaneously earned him UCLA’s Outstanding Graduate Student and Outstanding Ph.D. awards. Dr. Gau recently received UCLA’s prestigious Distinguished Young Alumnus Award.

 

 

Directors & Advisors

Dr. Chih-Ming Ho – Chairman of the Board

At UCLA, Dr. Ho currently holds the Ben Rich-Lockheed Martin Professor Chair in the School of Engineering, serves as the Associate Vice Chancellor of Research, and heads the Institute for Cell Mimetic Space Exploration (CMISE) as Director. He is world-renowned for his work in MEMS and microfluidics and is a member or Fellow of numerous honorary societies, including the National Academy of Engineering, the American Physical Society, the American Institute of Aeronautics and Astronautics. He has extensive experience working with startup companies and is currently on the Scientific Advisory Board of Capital Biochip, the largest biochip company in China. Dr. Ho received his B.S. from National Taiwan University and his Ph.D. from Johns Hopkins University.

 

Research Partners

GeneFluidics has a number of partners for research in novel assay development. Non-confidential relationships include:

UCLA Department of Urology

GeneFluidics and the Department of Urology at UCLA are collaborating on the development of a rapid uropathogen screening system. The project is funded by the National Institute of Biomedical Imaging and Bioengineering at the National Institutes of Health.

UCLA Department of Dental and Oral Biology

GeneFluidics and the Department of Dental and Oral Biology at UCLA are co-developing a point-of-care salivary diagnostics device, the first point-of-care device for head and neck cancer screening.

Veterans Affairs Hospital, Los Angeles

GeneFluidics and the Los Angeles VA Hospital are collaborating on the development of a rapid antibiotic suceptibility testing system. The project is funded by the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

Veterans Affairs Hospital, Palo Alto, Stanford University

GeneFluidics and the VA Palo Alto Hospital are collaborating on the development of a rapid pathogen identification point-of-care system. The project is funded by the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

Distribution

GeneFluidics’ sensor chip products are being non-exclusively distributed by Fisher Scientific.